Sientra (NASDAQ:SIEN) posted its quarterly earnings data on Tuesday. The medical instruments supplier reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.21), Briefing.com reports. The business had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $11.90 million. Sientra had a negative net margin of 169.77% and a negative return on equity of 68.82%. The firm’s quarterly revenue was up 70.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.43) earnings per share.
Sientra (NASDAQ:SIEN) traded down $0.50 during trading on Wednesday, hitting $9.53. The stock had a trading volume of 42,840 shares, compared to its average volume of 326,645. The stock has a market capitalization of $201.39, a PE ratio of -3.52 and a beta of -1.10. Sientra has a 1-year low of $7.20 and a 1-year high of $16.68. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.87 and a quick ratio of 1.92.
A number of analysts have recently commented on SIEN shares. ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub cut Sientra from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Stifel Nicolaus upgraded Sientra from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Friday, January 19th. Zacks Investment Research upgraded Sientra from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 24th. Finally, Lake Street Capital cut Sientra from a “buy” rating to a “hold” rating and cut their price objective for the company from $15.00 to $11.00 in a research report on Wednesday, February 21st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $14.00.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.